IDEXX Laboratories, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.6 (market cap $7.77B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| IDXX | PDBC | |
|---|---|---|
Market Cap | $40.43B | $7.77B |
Volume | 692,164 | 6,100,303 |
Sector | Health | — |
52-Week High | $766.68 | $20.10 |
52-Week Low | $504.70 | $13.16 |
Typical Hold Time | 46 Days | 56 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.66, up 1.29% with strong bullish momentum from moving averages. The ETF has delivered exceptional performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows significant position increases despite a 215% surge in short interest in September.
The outlook remains positive given strong commodity trends and defensive positioning benefits, though elevated short interest and RSI levels near overbought territory suggest potential near-term volatility. Commodity exposure provides inflation hedging advantages but remains sensitive to geopolitical developments and global economic conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →